October 03, 2025

Pembrolizumab Plus Platinum-Based Chemotherapy in Advanced Penile Cancer

In a Brazilian phase II trial (HERCULES; LACOG 0218) reported in JAMA Oncology, Maluf et al found that pembrolizumab plus platinum-based chemotherapy showed activity in patients with advanced penile s...

The ASCO Post

March 24, 2023

Expert Point of View: Xin Gao, MD

Dr. Xin Gao from Harvard Medical School shares new insights on sacituzumab govitecan's efficacy in metastatic urothelial cancer patients and examines future research prospects.

The ASCO Post

June 05, 2023

Study Sends Strong Signal Not to Sequence Immune Checkpoint Inhibitors in Advanced Kidney Cancer

Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor treatment in metastatic renal cell carcinoma: primary PFS analysis from the Phase 3, randomized, open-label CONTACT-03 study

Dana-Farber

July 11, 2024

Association of Genetic Risk for Prostate Cancer With Early Prostate Cancer Death

A recent cohort study found that men at a higher genetic risk for prostate cancer were more likely to experience early death from prostate cancer compared to men with a lower genetic risk for the dise...

The ASCO Post

August 15, 2023

Study Shows Immunotherapy May Benefit a Subset of Patients with Penile Cancer

Penile cancer is a rare disease with approximately 2070 new cases each year in the US.

Dana-Farber

June 27, 2025

Prostate Cancer: Biomarker Test May Predict GU Toxicity From SBRT

Researchers have validated a biomarker test for predicting the development of genitourinary adverse effects induced by stereotactic body radiotherapy (SBRT) in patients with prostate cancer, according...

The ASCO Post

February 20, 2023

Single-Arm Phase II Noninferiority Trial Evaluates Active Surveillance vs Cystectomy Following Neoadjuvant Chemotherapy for Muscle-Invasive Urothelial Carcinoma

Researchers have found that following chemotherapy, 46% of patients with muscle-invasive urothelial carcinoma were able to avoid a cystectomy and achieve a 2-year metastasis-free survival, according t...

The ASCO Post

March 10, 2023

TRITON3 Trial: Rucaparib Extends Progression-Free Survival in Selected Patients With Metastatic Castration-Resistant Prostate Cancer

The poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib prolonged imaging-based progression-free survival vs physician’s choice of therapy in patients with metastatic castration-resistant prostate...

The ASCO Post

February 06, 2025

Results From FIRE-4 Show Liquid Biopsy Can Detect RAS/BRAF-Mutated Metastatic Colorectal Cancer

The results from the phase III FIRE-4 randomized clinical trial showed that liquid biopsy accurately identified patients with RAS/BRAF V600E wild type-mutated metastatic colorectal cancer. These findi...

The ASCO Post